RxDoctor Payments Data

Honey Chapman, APRN

Family · Sumter, SCNPI 1114653185

Payments from drug & device makers

$598in general payments, 2019–2025

Across 19 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$411
  • Novo Nordisk$69
  • Otsuka America Pharmaceutical, Inc.$33
  • Teva Pharmaceuticals USA, Inc.$22
  • Novartis$17
  • Lilly USA, LLC$16
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$598100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$598 in reported general payments places this provider in the 55th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$75,584
Medicare patients
272
Services billed
2,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$38,150
FarxigaDapagliflozin Propanediol52$34,628
TrulicityDulaglutide11$13,681
JanuviaSitagliptin Phosphate15$11,702
JardianceEmpagliflozin13$11,027
RybelsusSemaglutide11$10,099
EliquisApixaban14$9,713
LinzessLinaclotide12$8,678
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,407
XareltoRivaroxaban11$7,164
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$4,696
Arnuity ElliptaFluticasone Furoate11$2,754
Albuterol Sulfate HfaAlbuterol Sulfate58$1,307
Esomeprazole Magnesium41$1,104
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine29$1,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$16$51,83140 claims
Novo NordiskRybelsus$69$10,09911 claims
PfizerEliquis$16$9,71314 claims
AbbVieLinzess$411$8,67812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,248 family providers in South Carolina.

Other family in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →